vs

Side-by-side financial comparison of NEOGEN CORP (NEOG) and PHOTRONICS INC (PLAB). Click either name above to swap in a different company.

NEOGEN CORP is the larger business by last-quarter revenue ($224.7M vs $210.4M, roughly 1.1× PHOTRONICS INC). PHOTRONICS INC runs the higher net margin — 10.9% vs -7.1%, a 18.0% gap on every dollar of revenue. On growth, NEOGEN CORP posted the faster year-over-year revenue change (-2.8% vs -5.5%). PHOTRONICS INC produced more free cash flow last quarter ($25.2M vs $7.8M). Over the past eight quarters, NEOGEN CORP's revenue compounded faster (-0.9% CAGR vs -3.8%).

Neogen Corporation is an international food safety company that provides test kits and relevant products to detect dangerous substances in food. The company was founded in 1982 and is based in Lansing, Michigan. The company serves a wide range of countries including Canada, United States, the United Kingdom, parts of Europe, Mexico and Brazil, India, and China, among others. The company operates a product line of over 100 drug detection test kits worldwide for the detection of about 300 abuse...

Photronics, Inc. is an American semiconductor photomask manufacturer. It was the third largest photomask supplier globally as of 2009. Photronics is a member of the eBeam Initiative.

NEOG vs PLAB — Head-to-Head

Bigger by revenue
NEOG
NEOG
1.1× larger
NEOG
$224.7M
$210.4M
PLAB
Growing faster (revenue YoY)
NEOG
NEOG
+2.7% gap
NEOG
-2.8%
-5.5%
PLAB
Higher net margin
PLAB
PLAB
18.0% more per $
PLAB
10.9%
-7.1%
NEOG
More free cash flow
PLAB
PLAB
$17.4M more FCF
PLAB
$25.2M
$7.8M
NEOG
Faster 2-yr revenue CAGR
NEOG
NEOG
Annualised
NEOG
-0.9%
-3.8%
PLAB

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
NEOG
NEOG
PLAB
PLAB
Revenue
$224.7M
$210.4M
Net Profit
$-15.9M
$22.9M
Gross Margin
47.5%
33.7%
Operating Margin
-2.4%
22.9%
Net Margin
-7.1%
10.9%
Revenue YoY
-2.8%
-5.5%
Net Profit YoY
96.5%
-32.4%
EPS (diluted)
$-0.07
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEOG
NEOG
PLAB
PLAB
Q4 25
$224.7M
Q3 25
$209.2M
$210.4M
Q2 25
$225.4M
$211.0M
Q1 25
$221.0M
$212.1M
Q4 24
$231.3M
$222.6M
Q3 24
$217.0M
$211.0M
Q2 24
$236.8M
$217.0M
Q1 24
$228.8M
$216.3M
Net Profit
NEOG
NEOG
PLAB
PLAB
Q4 25
$-15.9M
Q3 25
$36.3M
$22.9M
Q2 25
$-612.3M
$8.9M
Q1 25
$-10.9M
$42.9M
Q4 24
$-456.3M
$33.9M
Q3 24
$-12.6M
$34.4M
Q2 24
$-5.4M
$36.3M
Q1 24
$-2.0M
$26.2M
Gross Margin
NEOG
NEOG
PLAB
PLAB
Q4 25
47.5%
Q3 25
45.4%
33.7%
Q2 25
41.2%
36.9%
Q1 25
49.9%
35.6%
Q4 24
49.0%
37.0%
Q3 24
48.4%
35.6%
Q2 24
47.9%
36.5%
Q1 24
51.1%
36.6%
Operating Margin
NEOG
NEOG
PLAB
PLAB
Q4 25
-2.4%
Q3 25
-7.7%
22.9%
Q2 25
-271.1%
26.4%
Q1 25
2.4%
24.6%
Q4 24
-197.8%
25.1%
Q3 24
1.0%
24.7%
Q2 24
5.5%
25.8%
Q1 24
5.3%
26.6%
Net Margin
NEOG
NEOG
PLAB
PLAB
Q4 25
-7.1%
Q3 25
17.4%
10.9%
Q2 25
-271.6%
4.2%
Q1 25
-4.9%
20.2%
Q4 24
-197.3%
15.2%
Q3 24
-5.8%
16.3%
Q2 24
-2.3%
16.7%
Q1 24
-0.9%
12.1%
EPS (diluted)
NEOG
NEOG
PLAB
PLAB
Q4 25
$-0.07
Q3 25
$0.17
$0.39
Q2 25
$-2.82
$0.15
Q1 25
$-0.05
$0.68
Q4 24
$-2.10
$0.54
Q3 24
$-0.06
$0.55
Q2 24
$-0.02
$0.58
Q1 24
$-0.01
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEOG
NEOG
PLAB
PLAB
Cash + ST InvestmentsLiquidity on hand
$145.3M
$575.8M
Total DebtLower is stronger
$16.0K
Stockholders' EquityBook value
$2.1B
$1.1B
Total Assets
$3.4B
$1.8B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEOG
NEOG
PLAB
PLAB
Q4 25
$145.3M
Q3 25
$138.9M
$575.8M
Q2 25
$129.0M
$558.4M
Q1 25
$127.7M
$642.2M
Q4 24
$140.2M
$640.7M
Q3 24
$120.5M
$606.4M
Q2 24
$170.9M
$559.9M
Q1 24
$168.4M
$521.5M
Total Debt
NEOG
NEOG
PLAB
PLAB
Q4 25
Q3 25
$16.0K
Q2 25
$19.0K
Q1 25
$21.0K
Q4 24
$25.0K
Q3 24
$28.0K
Q2 24
$2.5M
Q1 24
$2.7M
Stockholders' Equity
NEOG
NEOG
PLAB
PLAB
Q4 25
$2.1B
Q3 25
$2.1B
$1.1B
Q2 25
$2.1B
$1.1B
Q1 25
$2.7B
$1.1B
Q4 24
$2.7B
$1.1B
Q3 24
$3.1B
$1.1B
Q2 24
$3.1B
$1.0B
Q1 24
$3.1B
$1.0B
Total Assets
NEOG
NEOG
PLAB
PLAB
Q4 25
$3.4B
Q3 25
$3.4B
$1.8B
Q2 25
$3.4B
$1.7B
Q1 25
$4.0B
$1.7B
Q4 24
$4.1B
$1.7B
Q3 24
$4.5B
$1.6B
Q2 24
$4.5B
$1.6B
Q1 24
$4.6B
$1.6B
Debt / Equity
NEOG
NEOG
PLAB
PLAB
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEOG
NEOG
PLAB
PLAB
Operating Cash FlowLast quarter
$19.4M
$50.1M
Free Cash FlowOCF − Capex
$7.8M
$25.2M
FCF MarginFCF / Revenue
3.5%
12.0%
Capex IntensityCapex / Revenue
5.2%
11.8%
Cash ConversionOCF / Net Profit
2.19×
TTM Free Cash FlowTrailing 4 quarters
$-18.5M
$64.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEOG
NEOG
PLAB
PLAB
Q4 25
$19.4M
Q3 25
$10.9M
$50.1M
Q2 25
$16.4M
$31.5M
Q1 25
$19.5M
$78.5M
Q4 24
$40.3M
$68.4M
Q3 24
$-17.9M
$75.1M
Q2 24
$26.7M
$76.5M
Q1 24
$-30.2M
$41.5M
Free Cash Flow
NEOG
NEOG
PLAB
PLAB
Q4 25
$7.8M
Q3 25
$-13.1M
$25.2M
Q2 25
$349.0K
$-29.1M
Q1 25
$-13.4M
$43.3M
Q4 24
$23.1M
$25.2M
Q3 24
$-56.3M
$50.7M
Q2 24
$2.5M
$56.5M
Q1 24
$-62.3M
$-1.8M
FCF Margin
NEOG
NEOG
PLAB
PLAB
Q4 25
3.5%
Q3 25
-6.3%
12.0%
Q2 25
0.2%
-13.8%
Q1 25
-6.1%
20.4%
Q4 24
10.0%
11.3%
Q3 24
-26.0%
24.0%
Q2 24
1.1%
26.0%
Q1 24
-27.2%
-0.8%
Capex Intensity
NEOG
NEOG
PLAB
PLAB
Q4 25
5.2%
Q3 25
11.5%
11.8%
Q2 25
7.1%
28.7%
Q1 25
14.9%
16.6%
Q4 24
7.4%
19.4%
Q3 24
17.7%
11.6%
Q2 24
10.2%
9.2%
Q1 24
14.0%
20.0%
Cash Conversion
NEOG
NEOG
PLAB
PLAB
Q4 25
Q3 25
0.30×
2.19×
Q2 25
3.55×
Q1 25
1.83×
Q4 24
2.02×
Q3 24
2.18×
Q2 24
2.11×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEOG
NEOG

Other$109.2M49%
Bacterial And General Sanitation$44.9M20%
Services$25.7M11%
Natural Toxins And Allergens$20.4M9%
Animal Care$8.9M4%
Genomics Services$6.3M3%
Biosecurity Products$4.6M2%
Life Sciences$1.4M1%

PLAB
PLAB

High End Integrated Circuits$53.6M25%
High End Flat Panel Displays$53.5M25%
KR$43.7M21%
Other$42.1M20%
Mainstream Flat Panel Displays$9.1M4%
Transferred At Point In Time$8.4M4%

Related Comparisons